Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Mabion SA

272:STU

Mabion SA

Actions
  • Price (EUR)3.80
  • Today's Change0.015 / 0.40%
  • Shares traded0.00
  • 1 Year change+3.92%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.

  • Revenue in PLN (TTM)139.86m
  • Net income in PLN37.39m
  • Incorporated2009
  • Employees226.00
  • Location
    Mabion SAgen. Mariana Langiewicza 60KONSTANTYNOW LODZKI 95-050PolandPOL
  • Phone+48 422077890
  • Fax+48 422032703
  • Websitehttps://www.mabion.eu/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.